<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04570345</url>
  </required_header>
  <id_info>
    <org_study_id>DAUHIRB-20-162</org_study_id>
    <nct_id>NCT04570345</nct_id>
  </id_info>
  <brief_title>3 Months Versus 12 Months Dual Antiplatelet Therapy After Drug-eluting Stent Implantation in STEMI</brief_title>
  <acronym>BULK-STEMI</acronym>
  <official_title>3 Months Versus 12 Months Dual Antiplatelet Therapy After Second Generation Sirolimus Stent Implantation in ST-elevation Myocardial Infarction(BULK-STEMI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the clinical outcomes of dual antiplatelet therapy with aspirin and P2Y12 receptor&#xD;
      inhibitor vs. ticagrelor monotherapy at 3 months after PCI in patients with ST-elevation&#xD;
      myocardial infarction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the use of ticagrelor alone versus P2Y12 receptor&#xD;
      inhibitor and aspirin together after PCI among ST-elevation myocardial infarction patients&#xD;
      who complete 3-month course of dual antiplatelet therapy. The object of this study is to&#xD;
      determine the effectiveness and safety of ticagrelor alone, compared to P2Y12 receptor&#xD;
      inhibitor plus aspirin in reducing clinically relevant bleeding and in reducing ischemic&#xD;
      adverse events among patients diagnosed with ST-elevation myocardial infarction undergoing&#xD;
      PCI with second-generation drug-eluting stent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NACE: net clinical adverse event</measure>
    <time_frame>12 months after randomization</time_frame>
    <description>The sum of major adverse cardiac and cerebrovaascular event(MACCE) and bleeding event(BARC score)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major adverse cardiac and cerebrovaascular event(MACCE)</measure>
    <time_frame>12 months after randomization</time_frame>
    <description>Major adverse cardiac and cerebrovaascular event(MACCE) includes 1)all-cause motality, 2) acute MI, 3)cerebrovascular event, 4)stent thrombosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding (BARC type 3,5)</measure>
    <time_frame>12 months after randomization</time_frame>
    <description>The number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding).&#xD;
type 3a: Overt bleeding plus hemoglobin drop of 3 to &lt; 5 g/dL (provided hemoglobin drop is related to bleed); transfusion with overt bleeding, type 3b: Overt bleeding plus hemoglobin drop &lt; 5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents, type 3c: Intracranial hemorrhage confirmed by autopsy, imaging, or lumbar puncture; intraocular bleed compromising vision, type 5a: Probable fatal bleeding, type 5b: Definite fatal bleeding (overt or autopsy or imaging confirmation in accordance with BARC Definitions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual component of MACCE and bleeding episode</measure>
    <time_frame>12 months after randomization</time_frame>
    <description>All-cause mortality :Individual component of MACCE&#xD;
Acute MI :Individual component of MACCE&#xD;
Cerebrovascular event :Individual component of MACCE&#xD;
Stent thrombosis :Definite or probable stent thrombosis defined by Academic Research Consortium (ARC)&#xD;
Bleeding :Bleeding Academic Research Consortium (BARC) type 3 or 5</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1002</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Ticagrelor monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor monotherapy after 3-month DAPT(aspirin with ticagrelor)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin with P2Y12 receptor inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin with P2Y12 receptor inhibitor after 3-month DAPT(aspirin with ticagrelor)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ticagrelor monotherapy</intervention_name>
    <description>• Drug: ticagrelor monothearpy after first 3 months dual therapy</description>
    <arm_group_label>Aspirin with P2Y12 receptor inhibitor</arm_group_label>
    <arm_group_label>Ticagrelor monotherapy</arm_group_label>
    <other_name>Study group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin with P2Y12 receptor inhibitor</intervention_name>
    <description>• Drug: aspirin plus ticagrelor dual therapy during 12 months</description>
    <arm_group_label>Aspirin with P2Y12 receptor inhibitor</arm_group_label>
    <other_name>Control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 19 years old&#xD;
&#xD;
          -  Patients who received new generation sirolimus-eluting (Osiro®) stent implantation for&#xD;
             treating ACS&#xD;
&#xD;
          -  Provision of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 80 years&#xD;
&#xD;
          -  Pregnant women or women with potential childbearing&#xD;
&#xD;
          -  Life expectancy &lt; 1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyungil Park, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dong-A University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyungil Park, Ph.D</last_name>
    <phone>82-51-240-2733</phone>
    <email>cardiopark@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Internal Medicine,Dong-A University College of Medicine</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyungil Park, MD</last_name>
      <phone>82-51-240-2733</phone>
      <email>sotier@dau.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>YoungRak Cho, MD</last_name>
      <phone>82-10-8553-0723</phone>
      <email>progress2090@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>December 18, 2020</last_update_submitted>
  <last_update_submitted_qc>December 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dong-A University</investigator_affiliation>
    <investigator_full_name>Kyungil Park</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

